VivoSeq
Oncology

Circulating Tumor Cells

0

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

Circulating Tumor Cells is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

17/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Unknown status4 · 67%
Completed1 · 17%
Withdrawn1 · 17%

Clinical Trials

Trial Activity

6 trials

Circulating Tumor Cells and Tumor DNA in HCC and NET
Completed·UUniversity of Aarhus·N/A·NCT02973204·167 enrolled
Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC
Withdrawn·TThe Netherlands Cancer Institute·Phase 2·NCT04648189
A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells
Unknown status·—·N/A·NCT04521491·184 enrolled
Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer
Unknown status·FFudan University·N/A·NCT01671891·100 enrolled
Screening of Tobacco-induced Cancers by Low-dose CT-scanner and Identification of Circulating Tumor Cells
Unknown status·FFondation Hôpital Saint-Joseph·N/A·NCT02849041·176 enrolled
Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)
Unknown status·EErasmus Medical Center·Phase 2·NCT03050866·140 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)